I went back and watched the video again. Gregg Linn stresses how it doesn't make sense for a small company to spend the money to develop a drug like OvaDx and again they are going to license or sell it. He also talks at the beginning how when he was speaking with GC and GC said he planned to spin the Dx division out and Greg said " do you think this is really good time to do this?- I've got a better idea"

I think the reason GC sold the Dx to ADVX is becasue ADVX is going to be licensing OvaDX in the near future and will be getting A LOT of upfront cash. Once they do that, they won't have any assets left so they needed something to replace OvaDx and they will then have the cash to develop the AMBS assets- more cash than what GC could have raised on his own. I could see OvaDX getting a big upfront payment- maybe several tens of millions and then royalties/ milestones on the back-end. He is apparently in talks with Roche which he has already said, but probably others as well. These deals take many months to do- there is a lot of due diligence and negotiating. There seems to be a lot of consolidation in the DX business. Pretty much everything is owned by a few big companies like Quest and Lab Corp, so I would guess they would all interested.